Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease. When considering the Atara Biotherapeutics Inc stock dividend history, we have taken known splits into account, such that the ATRA dividend history is presented on a split-adjusted ("apples to apples") basis. Atara Biotherapeutics Inc dividend history is presented both in graphical/chart form, and as a ATRA dividend history data table along the right-hand column.
|
ATRA Stock Dividend HistoryThe ATRA dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable ATRA historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the ATRA dividend history record. Also see the ATRA stock dividend history data table along the right-hand column below. |
|
|
Hold (2.00 out of 4) 2nd percentile
(ranked lower than approx. 98% of all stocks covered)
Analysts' Target Price: ATRA Forecast Based on data provided by Zacks Investment Research via Quandl.com |